Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 217 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in... July 4, 2024 EMA Recommends Extension of Indications for Sugemalimab October 28, 2025 EMA Recommends Extension of Indications for Tislelizumab July 24, 2025 Bladder Cancer Trial Finds Extended Lymph Node Surgery Doesn’t Improve Survival November 6, 2024 Load more HOT NEWS Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases The long road to targeting the holy grail of the immune... Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in...
